Dr. Krampitz on Therapeutic Targets in pNETs

Geoffrey Krampitz, MD
Published: Thursday, Jan 21, 2016



Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors (pNETs).

Anti-CD47 agents and their safety profiles are currently being investigated in a phase I clinical trial, Krampitz explains. Community oncologists, he adds, should be aware of this class of drugs eventually coming down the pipeline.

Regarding safety, preclinical models reported low-grade anemia associated with anti-CD47 agents. However, this has not yet been observed in the phase I data, Krampitz adds.



Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors (pNETs).

Anti-CD47 agents and their safety profiles are currently being investigated in a phase I clinical trial, Krampitz explains. Community oncologists, he adds, should be aware of this class of drugs eventually coming down the pipeline.

Regarding safety, preclinical models reported low-grade anemia associated with anti-CD47 agents. However, this has not yet been observed in the phase I data, Krampitz adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x